01 August 2006

Mortality rate is twice as high in patients with pneumonia caused by highly resistant bacteria

Patients suffering from hospital-acquired pneumonia caused by a type of bacteria that is highly resistant to virtually all antibiotics are twice as likely to die as patients infected with other, less resistant bacteria. A study published today in the journal Critical Care shows for the first time that the highly resistant, metallo-beta-lactamase-producing Pseudomonas aeruginosa is associated with a much higher mortality rate than other types of the bacteria in patients with hospital-acquired pneumonia. The authors conclude that this may be due to the use of inappropriate antimicrobial treatments for infections with metallo-beta-lactamase-producing P. aeruginosa, and suggest that therapeutic approaches should be reviewed in hospitals with high prevalence of the bacteria.

Alexandre Zavascki from Universidade Federal do Rio Grande do Sul in Porto Alegre, Brazil, and colleagues from other institutions in Brazil studied 150 patients admitted to two hospitals in Porto Alegre and suffering from hospital-acquired pneumonia.

The results of Zavascki et al.'s study show that 42 patients were infected with metallo-beta-lactamase-producing P. aeruginosa. For these patients, the 30-day mortality rate was 57.1%, compared with 29.6% for patients infected with other P. aeruginosa strains. Only half of the patients infected with the highly resistant bacteria were treated with appropriate antibiotics. But even when the recommended treatment was used, mortality was still high, suggesting that the optimal treatment for these highly resistant bacteria is yet to be found.

# # #

Article:
Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-b-lactamases-mediated multidrug resistance: a prospective observational study
Alexandre P Zavascki, Afonso L Barth, Juliana F Fernandez, Ana Lucia D Moro, Ana Lucia S Goncalves and Luciano Z Goldani
Critical Care 2006, 10:R114 (1 August 2006)

Journal website:
http://ccforum.com/

Please name the journal in any story you write, and link to the article if you are writing for the web.

# # #

For more information about this study, or about the journal, contact Juliette Savin by email at press@biomedcentral.com or by phone on +44 (0)20 7631 9931

# # #

BioMed Central (http://www.biomedcentral.com) is an independent online publishing house committed to providing open access to peer-reviewed biological and medical research. This commitment is based on the view that immediate free access to research and the ability to freely archive and reuse published information is essential to the rapid and efficient communication of science.

BioMed Central currently publishes over 160 journals across biology and medicine. In addition to open-access original research. BioMed Central also publishes reviews, commentaries and other non-original-research content. Depending on the policies of the individual journal, this content may be open access or provided only to subscribers.